BALTIMORE, MD--(Marketwired - Sep 18, 2013) - In a newly released article, Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, notes that Nuvilex, Inc. (
On the heels of last week's cell storage contract with Fisher BioServices, Nuvilex announced that it has contracted with Inno Biologics for the generation of clones from the cells that are basis of the Company's future Phase 3 cancer clinical trials. As important as the Fisher BioServices contract is from the developmental and status affirmation perspectives, one could argue that the Inno Biologics deal is an even more significant event. The clone production is the most obvious and tangible illustration that Nuvilex has taken a major step toward future Phase 3 cancer clinical trials, and here is why.
The generation of clones of these cells represents the initial step in the preparation of the large number of cancer drug-activating cells that ultimately will be required for encapsulation. These cells are the same ones used in previous clinical trials and will be used by the Company for cancer trials including its future planned clinical trials against advanced, inoperable pancreatic cancer. Therefore, this event should be interpreted by investors as the greatest tangible evidence of Nuvilex's direct development activity and its complete commitment to further its advanced clinical trial efforts.
Initially, a large number of individual clones will be generated by Inno Biologics from the cells supplied to them. Isolated clones will be tested to determine the best for Nuvilex's use through recognizing clones with the highest CYP 2B1 enzyme activity. The CYP 2B1 enzyme is the critical ifosfamide cancer-drug-activating enzyme in these cells that is the basis for the Nuvilex treatment to fight pancreatic cancer.
Once clones have been recognized and undergone initial assessment, the Company will continue to advance the clones through a series of validations necessary to prepare them for use in clinical trials.
It is clear that the cell storage and cell cloning are just two of many milestone events for Nuvilex in the near term. Other, future catalytic events include mass production of clones and cells that carry identical properties will be stored by Fisher BioServices for Nuvilex's use in future trials. All in all, Nuvilex's stock value should be afforded a significant boost with the initiation and completion of each phase, including the just-launched cell cloning activity, as demonstrative progress toward Phase 3 trials occurs.
To view all of our sponsored Nuvilex reports, updates, articles, disclosures and disclaimers, or to download the article in its entirety, please visit www.goldmanresearch.com.
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.
A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.
About Nuvilex, Inc. (